文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局限性前列腺癌点扫描质子放疗基于前列腺特异性膜抗原正电子发射断层扫描的五年结局:单机构经验

Five-Year Prostate-Specific Membrane Antigen Positron Emission Tomography-Based Outcomes of Spot-Scanning Proton Radiation Therapy for Localized Prostate Cancer: A Single Institution Experience.
PubMed 文献 · Adv Radiat Oncol · 2024-09-18

本研究前瞻性登记2016年1月至2018年12月接受点扫描质子治疗(SSPT)的284例前列腺癌患者,中位随访4.4年,评估5年总生存、局部控制、生化失败及不良事件。常规分割、大分割和立体定向体部放疗的5年局部控制率分别为100%、100%和97.3%(P=0.07),全组生化失败率为6.7%。SSPT在不同分割方案下均提供高局部控制率和良好肿瘤学结局,长期不良事件率低。

要点

  • 全组生化失败率为6.7%,常规分割、大分割和立体定向体部放疗的5年局部控制率分别为100%、100%和97.3%(P=0.07)。
  • 5年总生存率在常规分割、大分割和立体定向体部放疗组分别为88.1%、86.1%和97.2%(P=0.1)。
  • 急性和慢性≥2级胃肠道不良事件分别发生于8例(2.8%)和51例(18.0%),≥3级分别发生于3例(1.1%)和4例(1.4%)。

核心结论

  • SSPT在不同分割方案下均提供高局部控制率和良好肿瘤学结局,且长期不良事件率低。

研究设计与样本

  • 前瞻性登记研究,纳入2016年1月至2018年12月接受SSPT的前列腺癌患者284例,中位随访4.4年。

主要发现

  • 全组生化失败率为6.7%,生化失败定义为前列腺特异性抗原较最低值升高≥2.0 ng/mL。
  • 常规分割、大分割和立体定向体部放疗的5年局部控制率分别为100%、100%和97.3%(P=0.07)。
  • 区域复发共12例(4.2%),其中常规分割8例、大分割2例、立体定向体部放疗2例(P=0.62)。
  • 远处失败共12例(4.2%),其中常规分割5例、大分割7例、立体定向体部放疗0例(P=0.05)。
  • 5年总生存率在常规分割、大分割和立体定向体部放疗组分别为88.1%、86.1%和97.2%(P=0.1)。

关键数值与推荐

  • 常规分割中位总剂量为79.2 Gy/44次,大分割为70 Gy/28次,立体定向体部放疗为38 Gy/5次。
  • 急性和慢性≥2级胃肠道不良事件分别发生于8例(2.8%)和51例(18.0%),≥3级分别发生于3例(1.1%)和4例(1.4%)。
  • 急性和慢性≥2级泌尿生殖系统不良事件分别发生于71例(25%)和63例(22.2%),≥3级分别发生于3例(1.1%)和6例(2.1%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report 5-year oncologic outcomes of a prospective series of patients with prostate cancer treated with spot-scanning proton therapy (SSPT). METHODS AND MATERIALS: A prospective registry identified patients with prostate cancer treated with SSPT between January 2016 and December 2018. Five-year overall survival, local control, biochemical failure, regional and distant failures, and adverse events (AEs) were assessed. Biochemical failure was defined as rise in prostate-specific antigen ≥ 2.0 ng/mL above nadir prostate-specific antigen. Baseline-adjusted toxicities were assigned using the Common Terminology Criteria for Adverse Events version 5.0. RESULTS: With a median follow-up of 4.4 years, 284 patients with prostate cancer were treated with SSPT. Median total radiation dose was 79.2 Gy over 44 fractions, 70 Gy over 28 fractions, and 38 Gy over 5 fractions for conventional fractionation (CF), hypofractionation (HF), and stereotactic body radiation therapy (SBRT), respectively. Biochemical failure rate for all patients was 6.7%. Five-year local control rates for CF, HF, and SBRT were 100%, 100%, and 97.3%, respectively (P = .07). Regional recurrences occurred in 12 (4.2%) patients: 8 treated with CF, 2 with HF, and 2 with SBRT (P = .62). Distant failures occurred in 12 patients (4.2%): 5 treated with CF, 7 with HF, and none with SBRT (P = .05). Five-year overall survival for patients treated with CF, HF, and SBRT SSPT were 88.1%, 86.1%, and 97.2%, respectively (P = .1). Acute and chronic grade 2+ gastrointestinal AEs occurred in 8 (2.8%) and 51 (18.0%) patients, respectively. Acute and chronic grade 3+ gastrointestinal AEs occurred in 3 (1.1%) and 4 (1.4%) patients, respectively. Acute and chronic grade 2+ genitourinary-related AEs were observed in 71 (25%) and 63 (22.2%) patients, respectively. Acute and chronic grade 3+ genitourinary toxicity were observed in 3 (1.1%) and 6 (2.1%) patients, respectively. CONCLUSIONS: SSPT provides high local control rates and excellent oncologic outcomes across different fractionation schedules with low long-term AE rates.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sperduto W, Voss MM, Laughlin B, et al. Five-Year Prostate-Specific Membrane Antigen Positron Emission Tomography-Based Outcomes of Spot-Scanning Proton Radiation Therapy for Localized Prostate Cancer: A Single Institution Experience. Adv Radiat Oncol. 2024. PMID: 39610799. doi:10.1016/j.adro.2024.101639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。